Covid-19 Nasal Vaccine Produces Antibodies, Cuts Viral Load

Tests with lab animals show a vaccine given as a nasal spray produces high antibody volumes against SARS-CoV-2 infections and reduces viral loads. Results of tests by biotechnology companies Oragenics Inc., a Sid Martin Biotech alum located in Tampa, and Inspirevax in Laval, Quebec, with National Research Council of Canada, appear on the bioRxiv pre-publication server, and are not yet peer-reviewed.

Oragenics creates vaccines and treatments for infectious diseases, focusing recently on the Covid-19 pandemic, but also multi-drug resistant microorganisms. For Covid-19, the company is developing a next-generation vaccine called Terra CoV-2 with a synthetic protein technology licensed from National Institutes of Health and National Research Council of Canada. Oragenics says its platform enables design of new vaccines targeting the SARS-CoV-2 spike protein in six to eight weeks, making it possible to respond quickly to future variants.

Read more about Covid-19 Nasal Vaccine Produces Antibodies, Cuts Viral Load.